-
Let InBios Fuel Your Next Breakthrough
The high-quality, well-characterized monoclonal antibodies that power InBios' diagnostics are now available to the research community, suitable for a range of applications including ELISA and rapid immunochromatographic assays. -
Let InBios Fuel Your Next Breakthrough
The high-quality, well-characterized monoclonal antibodies that power InBios' diagnostics are now available to the research community, suitable for a range of applications including ELISA and rapid immunochromatographic assays. -
Let InBios Fuel Your Next Breakthrough
The high-quality, well-characterized monoclonal antibodies that power InBios' diagnostics are now available to the research community, suitable for a range of applications including ELISA and rapid immunochromatographic assays. -
Your Next Breakthrough Starts Here
For over 25 years, InBios has been a trusted leader in the development and manufacture
of diagnostic test kits for emerging infectious diseases. The same high-quality,
well-characterized monoclonal antibodies that power our diagnostics are now available to the research community, suitable for a range of applications including ELISA and rapid immunochromatographic assays. -
Let InBios Fuel Your Next Breakthrough
The high-quality, well-characterized monoclonal antibodies that power InBios' diagnostics are now available to the research community, suitable for a range of applications including ELISA and rapid immunochromatographic assays. -
Your Next Breakthrough Starts Here
For over 25 years, InBios has been a trusted leader in the development and manufacture
of diagnostic test kits for emerging infectious diseases. The same high-quality,
well-characterized monoclonal antibodies that power our diagnostics are now available to the research community, suitable for a range of applications including ELISA and rapid immunochromatographic assays. -
New Expanded Line of FDA-Cleared
Respiratory Diagnostics
CLIA-waived Point of Care:
COVID-19 & Flu A&B • COVID-19 • Strep A
Over The Counter:
COVID-19 & Flu A&B • COVID-19 -
AI-POWERED LYME DIAGNOSTICS:
The Future is Multiplexed!Visit us at the upcoming ADLM conference to learn more about our novel test for early,
sensitive, specific detection of antibodies to support diagnosis of Lyme disease.
McCormick Place Convention Center, Chicago, IL
Tuesday, July 29th
11:30 - 11:50am -
Coming Soon:
Lyme Detect™ Multiplex ELISAAn innovative array-based immunoassay in a traditional ELISA plate format.
• For Research Use Only
• Includes specific B. burgdorferi target antigens
• Simultaneous IgG and IgM detection
• Automated analyses
• Machine learning guided interpretations
• Enhanced workflow - no sequential testing required
• Lower cost/patient result -
InBios’ POC COVID-19 Rapid Test now
FDA 510(k) Cleared and CLIA Waived -
Now FDA-Cleared!
InBios' COVID-19 Detect™ Rapid Self-Test -
An Accurate Diagnosis is the First Step to Effective Treatment
Improving health outcomes globally through the revolutionary design, rapid development and state-of-the-art manufacture of superior quality immunodiagnostics for infectious diseases.
-
An Accurate Diagnosis is the First Step to Effective Treatment
Improving health outcomes globally through the revolutionary design, rapid development and state-of-the-art manufacture of superior quality immunodiagnostics for infectious diseases.
-
Ask About our Products for Emerging Infectious Diseases and Biothreats
COVID-19 • Zika • Chikungunya • Dengue • West Nile • Japanese Encephalitis • Scrub Typhus • Visceral Leishmaniasis • Babesia • Cutaneous Leishmaniasis • Chagas • Filariasis • Strongyloides • Melioidosis • Norovirus • Anthrax
Spotlight on Global Health: Chikungunya
About 5.6 billion people across 119 countries live in areas at risk of the virus.
- Chikungunya is spreading across the world with epidemic transmission in South Asia. The CDC has issued travel alerts.
- Europe is experiencing imported cases, with local transmission in France and suspected cases emerging in Italy.
InBios’ highly-regarded chikungunya IgM and IgG assays are in demand. Contact us today to learn more.
What We Do
InBios improves health outcomes by providing superior quality diagnostic products
that are accurate, easy to use and cost effective.
Featured News & Events
News
Events
How InBios Products Improve Health Outcomes
Experience
Privately owned since our founding in 1996, InBios has a talented team of scientists and engineers with over 25 diagnostic products and an extensive catalog of life science reagents on the market. Our committed leadership team drives innovation to continuously raise the standard of quality for our products.
Superior Quality
InBios has nearly 25 years of experience and an unwavering commitment to quality. All products are manufactured in our state-of-the-art facility in Seattle, WA, USA, and we are GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. This commitment to quality results in products that are accurate and user friendly.
Responsiveness to Emerging Diseases
With our expertise in emerging diseases and biothreats, our staff can readily respond to the latest infectious disease threat. We have proven success in navigating the regulatory pathways to react quickly and speed products to clinical labs to meet urgent diagnostic demands.
Cost Effectiveness
While quality is of utmost importance, InBios also strives to produce products that are cost effective, an important factor in serving the global marketplace where fast, easy-to-use diagnostics are critical.
